Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compositions and methods for treating neurodegenerative diseases
Azevan Pharmaceuticals, Inc.
June 22, 2017 - N°20170174670

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as huntington's disease, parkinson's disease, and alzheimer's disease.
Botulinum toxin treatments of neurological and neuropsychiatric disorders
Allergan, Inc.
June 22, 2017 - N°20170173123

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/...
Substituted imidazo[1,5-a]pyrazines as pde9 inhibitors
Allergan, Inc.
June 22, 2017 - N°20170173018

The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (i). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions
Takeda Pharmaceutical Company Limited
June 15, 2017 - N°20170166553

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, in which r1, r2, r3, r4 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-i
Merck Sharp & Dohme Corp.
June 08, 2017 - N°20170158628

The present invention relates to chemical compounds of formula (i), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nachr). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ...
Anti-depression compounds
Board Of Regents Of The University Of Texas System
June 08, 2017 - N°20170157092

This technology relates generally to compounds and methods for stimulating neurogenesis (e. G., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted pyrazino[2,2-a]isoquinoline derivatives
Centre For Addiction And Metal Health
May 25, 2017 - N°20170145010

The present invention relates to compounds of formula of formula i wherein r, r2and l are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
Substituted azetidine derivatives
Centre For Addiction And Metal Health
May 25, 2017 - N°20170144994

The present invention relates to compounds of formula of formula i wherein r, r1. R2, r2′, r3, r4, r5, l1, l2 and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring ...
Centre For Addiction And Metal Health
May 25, 2017 - N°20170143959

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or ...
Mecp2e1 gene
Centre For Addiction And Mental Health
May 18, 2017 - N°20170137887

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives
Hoffmann-la Roche Inc.
May 18, 2017 - N°20170137435

The present invention relates to compounds of formula of formula i wherein x, l and r1 are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives
Hoffmann-la Roche Inc.
May 18, 2017 - N°20170137416

The present invention relates to compounds taar receptor antagonists of formula i wherein x, r, l, ar and r1 are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin a for the treatment of neuropsychiatric and ...
Hoffmann-la Roche Inc.
May 18, 2017 - N°20170135984

Methods of treating neuropsychiatric disorders including affective disorders and addiction involve intranasal or transdermal administration of a substantially selective kappa-opioid-receptor agonist that is also a partial d2 agonist, such as the compound salvinorin a. Also disclosed are intranasal, transdermal and/or inhalation systems for delivering the kappa-opioid-receptor agonist.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor ...
Vanderbilt University
May 11, 2017 - N°20170129889

In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using ...
Trpm8 antagonists
Vanderbilt University
May 11, 2017 - N°20170129881

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
Pattern analysis based on fmri data collected while subjects perform working memory tasks allowing high-precision ...
Northwestern University
May 04, 2017 - N°20170123028

Using a plurality of distinct behavioral tasks conducted in a functional magnetic resonance imaging (fmri) scanner, fmri data acquired from one or more subjects performing working memory tasks can be used for diagnosing psychiatrics and neurological disorders. A classification algorithm can be used to determine a classification model, tune the model, and apply the model. An output indicative of a ...
Orexin receptor antagonists
Northwestern University
May 04, 2017 - N°20170121320

Wherein w, x and y1, y2, y3 and y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
System and method for diagnosis and treatment of neuropsychiatric disorders
The Research Foundation For Mental Hygiene, Inc.
April 27, 2017 - N°20170114410

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered ...
Substituted prolines / piperidines as orexin receptor antagonists
Eolas Therapeutics, Inc.
April 13, 2017 - N°20170101410

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. ...
Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases
Eolas Therapeutics, Inc.
April 13, 2017 - N°20170100389

Tetrahydroprotoberbine (thpb) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-thpbs of general formula (i). Enantioselective processes for preparing compounds of formula (i), and d- and l-govadine are also provided.
Novel tricyclic modulators of cannabinoid receptors
The University Of Montana
April 06, 2017 - N°20170096426

The compounds of the invention are modulators of cannabinoid receptors cb1 or cb2. The compounds can be used for the prevention or treatment of, e. G., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases. The compounds of the invention can further be used to study these diseases and disorders, as well ...
Loading